The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Participation in SAYE Scheme

18 Oct 2017 09:00

RNS Number : 9229T
Omega Diagnostics Group PLC
18 October 2017
 

 

Omega Diagnostics Group PLC

("Omega" or the "Company")

 

PDMR participation in SAYE scheme

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that certain PDMRs of the Company have been granted sharesave option awards in the Company's save as you earn scheme ("SAYE Scheme") which gives them the opportunity to participate in the future growth of the Company via share award arrangements.

 

The SAYE Scheme grants participants the option to purchase ordinary shares of 4 pence each in the capital of the Company ("Ordinary Share") at a price of 18.4 pence per Ordinary Share and is exercisable between 1 November 2020 and 1 May 2021.

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

John Bannister

2.

Reason for notification

b)

Position / status

PDMR

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 4p each

 

GB00B1VCP282

b)

Nature of the transaction

Grant of share options under the Company's SAYE Scheme

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.184

23,478

 

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 October 2017

f)

Place of the transaction

Outside a trading venue

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Derek Brady

2.

Reason for notification

b)

Position / status

PDMR

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 4p each

 

GB00B1VCP282

b)

Nature of the transaction

Grant of share options under the Company's SAYE Scheme

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.184

14,673

 

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 October 2017

f)

Place of the transaction

Outside a trading venue

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Patrick Breen

2.

Reason for notification

b)

Position / status

PDMR

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 4p each

 

GB00B1VCP282

b)

Nature of the transaction

Grant of share options under the Company's SAYE Scheme

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.184

19,565

 

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 October 2017

f)

Place of the transaction

Outside a trading venue

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Michael Gordon

2.

Reason for notification

b)

Position / status

PDMR

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 4p each

 

GB00B1VCP282

b)

Nature of the transaction

Grant of share options under the Company's SAYE Scheme

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.184

39,130

 

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 October 2017

f)

Place of the transaction

Outside a trading venue

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Iain Logan

2.

Reason for notification

b)

Position / status

PDMR

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 4p each

 

GB00B1VCP282

b)

Nature of the transaction

Grant of share options under the Company's SAYE Scheme

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.184

9,782

 

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 October 2017

f)

Place of the transaction

Outside a trading venue

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Angela Robertson

2.

Reason for notification

b)

Position / status

PDMR

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 4p each

 

GB00B1VCP282

b)

Nature of the transaction

Grant of share options under the Company's SAYE Scheme

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.184

19,565

 

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 October 2017

f)

Place of the transaction

Outside a trading venue

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Edward Valente

2.

Reason for notification

b)

Position / status

PDMR

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 4p each

 

GB00B1VCP282

b)

Nature of the transaction

Grant of share options under the Company's SAYE Scheme

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.184

78,260

 

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 October 2017

f)

Place of the transaction

Outside a trading venue

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Jamie Yexley

2.

Reason for notification

b)

Position / status

PDMR

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 4p each

 

GB00B1VCP282

b)

Nature of the transaction

Grant of share options under the Company's SAYE Scheme

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.184

5,869

 

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 October 2017

f)

Place of the transaction

Outside a trading venue

 

Contacts:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

Jag Grewal, Group Sales and Marketing Director

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/James Thompson (Corporate Finance)

Mia Gardner (Corporate Broking)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFFDSWAFWSEES
Date   Source Headline
10th Apr 20187:00 amRNSStrategic Review of operations and Trading Update
12th Jan 201812:14 pmRNSHolding(s) in Company
21st Dec 20177:00 amRNSAllersys® CE-Mark
14th Dec 20177:01 amRNSCEO succession
14th Dec 20177:00 amRNSInterim results
29th Nov 20177:00 amRNSVISITECT® CD4 CE-Mark
1st Nov 20177:00 amRNSChange of Registered Office
23rd Oct 20177:00 amRNSTrading Update and Notice of Interim Results
18th Oct 20179:00 amRNSPDMR Participation in SAYE Scheme
16th Oct 20177:00 amRNSUS Supply Agreement
10th Oct 20177:00 amRNSHolding(s) in Company
5th Sep 20172:07 pmRNSExercise of Options and Total Voting Rights
29th Aug 201711:51 amRNSResult of AGM
18th Jul 201710:35 amRNSResult of General Meeting
6th Jul 201711:56 amRNSSale and leaseback of building owned by Omega GmbH
30th Jun 201712:13 pmRNSResult of Proposed Fundraising
30th Jun 20177:01 amRNSProposed Fundraising
30th Jun 20177:00 amRNSFinal Results
25th Apr 20177:00 amRNSTrading Update and Notice of Results
21st Apr 201712:41 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSVISITECT® Malaria CE-Mark & Indian FDA inspection
7th Mar 20178:45 amRNSHolding(s) in Company
27th Feb 201712:52 pmRNSHolding(s) in Company
27th Jan 20177:00 amRNSUpdate on discussions with IDS
11th Jan 20177:00 amRNSISO accreditation for manufacturing facility
29th Nov 20167:15 amRNSHardman Research: Food intolerance driving growth
24th Nov 20167:52 amRNSHolding(s) in Company
21st Nov 20167:00 amRNSHalf-year Report
31st Oct 20167:15 amRNSHardman Research: Diagnosing growth opportunities
17th Oct 20167:00 amRNSTrading Update and Notice of Interim Results
10th Aug 201612:22 pmRNSResult of AGM
2nd Aug 20167:00 amRNSR&D Grant Funding
4th Jul 20168:18 amRNSHolding(s) in Company
1st Jul 201611:48 amRNSHolding(s) in Company
27th Jun 20167:00 amRNSFinal Results
9th Jun 20169:07 amRNSHolding(s) in Company
21st Apr 20167:00 amRNSTrading Update & Notice of Results
8th Feb 20168:22 amRNSHolding(s) in Company
4th Dec 20154:25 pmRNSHolding(s) in Company
3rd Dec 201512:28 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSHalf Yearly Report
26th Oct 20157:00 amRNSTrading Update and Notice of Interim Results
30th Sep 20159:07 amRNSGrant of Options
7th Sep 20151:21 pmRNSResult of AGM
7th Jul 20157:00 amRNSFinal Results
5th Jun 201510:01 amRNSHolding(s) in Company
1st Jun 20157:00 amRNSDevelopment Update - Visitect® CD4 and Allergy
27th Apr 20157:00 amRNSBoard Appointment
15th Apr 20157:00 amRNSTrading update and Notice of Results
1st Dec 201410:37 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.